C07K 16/3038
Kidney, bladder
Official title: {Kidney, bladder}
C07K16/3038 (Kidney, bladder) appears on 377 US grants and 585 published applications in this corpus.
Search patents in C07K- Granted patents
- 377
- Published applications
- 585
- Assignees
- 172
- Inventors
- 669
- Latest grant
- 27 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 3 | 0 |
| 1988 | 2 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 3 | 0 |
| 1992 | 3 | 0 |
| 1993 | 6 | 0 |
| 1994 | 3 | 0 |
| 1995 | 0 | 0 |
| 1996 | 5 | 0 |
| 1997 | 7 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 0 | 8 |
| 2003 | 1 | 143 |
| 2004 | 5 | 11 |
| 2005 | 2 | 13 |
| 2006 | 5 | 5 |
| 2007 | 49 | 5 |
| 2008 | 28 | 5 |
| 2009 | 11 | 8 |
| 2010 | 6 | 16 |
| 2011 | 8 | 12 |
| 2012 | 3 | 13 |
| 2013 | 11 | 15 |
| 2014 | 10 | 22 |
| 2015 | 11 | 11 |
| 2016 | 23 | 52 |
| 2017 | 19 | 63 |
| 2018 | 33 | 30 |
| 2019 | 31 | 38 |
| 2020 | 27 | 20 |
| 2021 | 14 | 27 |
| 2022 | 16 | 24 |
| 2023 | 8 | 13 |
| 2024 | 10 | 12 |
| 2025 | 5 | 10 |
| 2026 | 2 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer27 Jan 2026US 12,534,530 B2Merck Sharp & Dohme Corp.
- Anti-VISTA antibodies and fragments6 Jan 2026US 12,516,122 B2Janssen Pharmaceutica NV
- Compositions and methods for adoptive cell therapy16 Dec 2025US 12,496,310 B2Memorial Sloan Kettering Cancer Center
- Systems and methods for targeting cancer cells11 Nov 2025US 12,466,892 B2The Regents of the University of California
- Methods of treating IL1RAP associated cancers with anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies26 Aug 2025US 12,398,213 B2Cantargia AB
- Anti-vista antibodies and fragments13 Aug 2026US 2026/0234264 A1Janssen Pharmaceutica NV
- Compositions including anti-wt-1 antibodies & antigen binding fragments and uses thereof6 Aug 2026US 2026/0226173 A1
- Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer30 Apr 2026US 2026/0116979 A1Merck Sharp & Dohme Corp.
- Systems and methods for targeting cancer cells19 Mar 2026US 2026/0078200 A1The Regents of the University of California
- Anti-pd-l1 combinations for treating tumors19 Feb 2026US 2026/0049145 A1Birdie Biopharmaceuticals, Inc.
Most cited
By later US patents
- Prostate-specific membrane antigen141US 5,538,866 ASloan-Kettering Institute for Cancer Research · 1996
- Monoclonal antibodies to prostate cells103US 5,489,525 AThe United States of America as represented by the Department of Health and Human Services · 1996
- Methods of treating acute myeloid leukemia by blocking CD4775US 8,562,997 B2The Board of Trustees of the Leland Stanford Junior University · 2013
- Purified human prostate antigen74US 4,446,122 AResearch Corporation · 1984
- Characterization of oncogenes and assays based thereon74US 4,535,058 AMassachusetts Institute of Technology · 1985